New drug may shield celiac patients from gluten damage
Disease control
Completed
This study tested a drug called KAN-101 in 55 adults with celiac disease who had been on a gluten-free diet for at least a year. Participants received either KAN-101 or a placebo, then underwent a two-week gluten challenge. The drug appeared to reduce gluten-induced damage to the…
Phase 2 • Sponsor: Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC